These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 25468252)

  • 41. Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale.
    Sinha AM; Diener HC; Morillo CA; Sanna T; Bernstein RA; Di Lazzaro V; Passman R; Beckers F; Brachmann J
    Am Heart J; 2010 Jul; 160(1):36-41.e1. PubMed ID: 20598970
    [TBL] [Abstract][Full Text] [Related]  

  • 42. My Approach to the use of NOACs for stroke prevention in patients with atrial fibrillation.
    Lip GY
    Trends Cardiovasc Med; 2014 Aug; 24(6):265-6. PubMed ID: 25106085
    [No Abstract]   [Full Text] [Related]  

  • 43. Antithrombotic therapies for stroke prevention in atrial fibrillation.
    Hart RG
    Adv Neurol; 2003; 92():249-56. PubMed ID: 12760190
    [No Abstract]   [Full Text] [Related]  

  • 44. Stroke prevention in atrial fibrillation: do we still need warfarin?
    Diener HC; Weber R; Lip GY; Hohnloser SH
    Curr Opin Neurol; 2012 Feb; 25(1):27-35. PubMed ID: 22143201
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Using the CHA(2)DS(2)-VASc score for stroke risk stratification in atrial fibrillation: a clinical perspective.
    Lip GY
    Expert Rev Cardiovasc Ther; 2013 Mar; 11(3):259-62. PubMed ID: 23469902
    [No Abstract]   [Full Text] [Related]  

  • 46. Evidenced-based pharmacotherapy for rate control in atrial fibrillation.
    Greenberg H
    Crit Care Nurs Q; 2013; 36(2):237-43. PubMed ID: 23470710
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation.
    Overvad TF; Larsen TB; Albertsen IE; Rasmussen LH; Lip GY
    Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1619-29. PubMed ID: 24215192
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Review of challenges in optimizing oral anticoagulation therapy for stroke prevention in atrial fibrillation.
    Fernandez MM; von Schéele B; Hogue S; Kwong WJ
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):87-102. PubMed ID: 23572283
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention.
    Poli D; Antonucci E; Grifoni E; Abbate R; Gensini GF; Prisco D
    Thromb Haemost; 2009 Feb; 101(2):367-72. PubMed ID: 19190823
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
    Agarwal S; Hachamovitch R; Menon V
    Arch Intern Med; 2012 Apr; 172(8):623-31; discussion 631-3. PubMed ID: 22450212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An anticoagulation option for nonvalvular atrial fibrillation.
    Shaheen MH; Das P; Koshy SK; Jha SK; Kabra R
    J Fam Pract; 2012 Jun; 61(6):E1-6. PubMed ID: 22670241
    [No Abstract]   [Full Text] [Related]  

  • 53. Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation.
    Liew A; Eikelboom JW; O'Donnell M
    Curr Opin Cardiol; 2012 Jul; 27(4):331-9. PubMed ID: 22573171
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevention of stroke in patients with atrial fibrillation.
    Med Lett Drugs Ther; 2009 Jun; 51(1313):41. PubMed ID: 19478692
    [No Abstract]   [Full Text] [Related]  

  • 55. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stroke prevention versus bleeding risk in atrial fibrillation: a clinical dilemma.
    Hohnloser SH
    J Am Coll Cardiol; 2011 Jan; 57(2):181-3. PubMed ID: 21111556
    [No Abstract]   [Full Text] [Related]  

  • 57. Anticoagulation control in atrial fibrillation: optimizing risks and benefits.
    Alsheikh-Ali AA; Estes NA
    Circ Cardiovasc Qual Outcomes; 2008 Nov; 1(2):72-3. PubMed ID: 20031792
    [No Abstract]   [Full Text] [Related]  

  • 58. Better prevention of stroke through screening for atrial fibrillation.
    James MA; Campbell JL
    Br J Gen Pract; 2012 May; 62(598):234-5. PubMed ID: 22546569
    [No Abstract]   [Full Text] [Related]  

  • 59. Novel anticoagulants for stroke prevention in atrial fibrillation and chronic kidney disease.
    Turagam MK; Addepally NS; Velagapudi P
    Expert Rev Cardiovasc Ther; 2013 Oct; 11(10):1297-9. PubMed ID: 24138517
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The EMBRACE study].
    Gaita F; Anselmino M; Sessa M
    G Ital Cardiol (Rome); 2015 Jan; 16(1):1-5. PubMed ID: 25689744
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.